NEW YORK CITY, NY / ACCESS Newswire / February 14, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law ...

Immunology superstar Dupixent, which first brought Regeneron and Sanofi together in 2007, has entered its megablockbuster era ...

The sessions may be accessed from the "Investors & Media" page of Regeneron's website at https://investor.regeneron.com/events-and-presentations. Replays and transcripts of the webcasts will be ...

This was the stock's second consecutive day of losses.

Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician ...

Biotech company Regeneron (NASDAQ:REGN) reported Q4 CY2024 results topping the market’s revenue expectations , with sales up 10.3% year on year to $3.79 billion. Its non-GAAP profit of $12.07 ...

Regeneron reported Q4 2024 earnings today - revenues were up 10% YoY to $3.79bn. Full-year revenues were up 8% to $14.2bn. Q4 GAAP EPS at $8.06, and $38 adj. full-year. The company declared its ...

Regeneron has started 2025 with an increase in defensive capital allocation - initiation of a dividend and an expanded share buyback program. Increased competitive pressure on the Eylea franchise ...

Regeneron Pharmaceuticals announced that the FDA has accepted the resubmission of its Biologics License Application (BLA) for linvoseltamab, an investigational treatment for adult patients with ...

It notched a convincing beat on net income. The quarter saw Regeneron grow its revenue by 10% year over year to just under $3.79 billion. Although non-GAAP (adjusted) net income didn't rise as ...